Drug Profile
Research programme: heat shock protein 90 inhibitors - Nerviano
Alternative Names: NMS-E973; NMS-P506Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Class
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Italy (IV)
- 19 Nov 2009 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 22 Apr 2009 Preclinical trials in Cancer in Italy (unspecified route)